Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids

被引：0
|
作者：
Talaulikar, Vikram Sinai [1 ]
Manyonda, Isaac [1 ]
机构：
[1] St Georges Hosp & Univ London, London SW17 0RE, England
来源：
WOMENS HEALTH | 2014年 / 10卷 / 06期
关键词：
fibroids; medical; myoma; SPRM; ulipristal acetate;
D O I：
10.2217/WHE.14.60
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.
引用
收藏
页码：565 / 570
页数：6
相关论文
共 50 条
  • [41] Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids
    Szydlowska, Iwona
    Grabowska, Marta
    Nawrocka-Rutkowska, Jolanta
    Kram, Andrzej
    Piasecka, Malgorzata
    Starczewski, Andrzej
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [42] ENDOMETRIAL SAFETY OF ULIPRISTAL ACETATE TREATMENT FOR SYMPTOMATIC UTERINE FIBROIDS IN PREMENOPAUSAL WOMEN - A SYSTEMATIC REVIEW
    Ples, Liana
    Carp, Delia
    Sima, Romina Marina
    Mirica, Alexandra
    Stanescu, Anca-Daniela
    Balalau, Denisa-Oana
    Balalau, Cristian
    FARMACIA, 2018, 66 (05) : 763 - 769
  • [43] Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial
    Osuga, Yutaka
    Nakano, Yasuaki
    Yamauchi, Yuji
    Takanashi, Masaya
    FERTILITY AND STERILITY, 2021, 116 (01) : 189 - 197
  • [44] Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results
    Fernandez, Herve
    Schmidt, Torsten
    Powell, Martin
    Freitas Costa, Ana Patricia
    Arriagada, Pablo
    Thaler, Christian
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 208 : 91 - 96
  • [45] Expulsion of a uterine myoma in a patient treated with ulipristal acetate
    Chantraine, Frederic
    Poismans, Gaelle
    Nwachuku, Julia
    Bestel, Elke
    Nisolle, Michelle
    CLINICAL CASE REPORTS, 2015, 3 (04): : 240 - 242
  • [46] Selective Progesterone Receptor Modulator(ulipristal acetate - a new option in the pharmacological treatment of uterine fibroids in women
    Szamatowicz, Marian
    Kotarski, Jan
    GINEKOLOGIA POLSKA, 2013, 84 (03) : 219 - 222
  • [47] Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program
    Donnez, Jacques
    Arriagada, Pablo
    Marciniak, Marcin
    Larrey, Dominique
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1225 - 1232
  • [48] Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
    Szydlowska, Iwona
    Marciniak, Aleksandra
    Nawrocka-Rutkowska, Jolanta
    Ryl, Aleksandra
    Starczewski, Andrzej
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (03)
  • [49] Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding
    Arendas, Kristina
    Leyland, Nicholas A.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2016, 38 (01) : 80 - 83
  • [50] Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study
    Giarre, Giovanna
    Franchini, Mario
    Castellacci, Eleonora
    Malune, Maria Elena
    Sardo, Attilio Di Spiezio
    Saccone, Gabriele
    Angioni, Stefano
    GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (02) : 171 - 174
12345